Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer by Kurzrock Razelle, Sherman Steven I, Ball Douglas W, Forastiere Arlene A, Cohen Roger B, Mehra Ranee, Pfister David G, Cohen Ezra E W, Janisch Linda, Nauling Forlisa, Hong David S, Ng Chaan S, Ye Lei, Gagel Robert F, Frye John, Müller Thomas, Ratain Mark J, Salgia Ravi in Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011).

[PMID: 21606412] PubMed


Discussed In Paper


Rx Annotations

No dosing information annotated.